Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice
An effective vaccine is essential for controlling the spread of the SARS-CoV-2 virus. Here, we describe an influenza virus-based vaccine for SARS-CoV-2. We incorporated a membrane-anchored form of the SARS-CoV-2 spike receptor binding domain (RBD) in place of the neuraminidase (NA) coding sequence i...
Main Authors: | Andrea N. Loes, Lauren E. Gentles, Allison J. Greaney, Katharine H. D. Crawford, Jesse D. Bloom |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/12/9/987 |
Similar Items
-
A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model
by: Surapong Koonpaew, et al.
Published: (2021-08-01) -
Safety and Efficacy of Spray Intranasal Live Attenuated Influenza Vaccine: Systematic Review and Meta-Analysis
by: Giulia Perego, et al.
Published: (2021-09-01) -
Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2
by: Tuksin Jearanaiwitayakul, et al.
Published: (2021-07-01) -
Neutralizing antibodies targeting SARS-CoV-2 spike protein
by: Shi Xiaojie, et al.
Published: (2021-01-01) -
A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2
by: Xiaojian Han, et al.
Published: (2021-03-01)